TES-4207 / TES Pharma - LARVOL DELTA

Oral NR2F6 Antagonist TES-4207 Targets Both Immune and Cancer Cells to Remodel Tumor Immune Response and Improve PD-1 Inhibitor Outcomes (EACR 2026) - "TES-4207 is the first orally available NR2F6 antagonist, capable of converting an immunologically "cold" tumor environment by boosting immune infiltration and slowing tumor progression targeting both immune cells as well as malignant cells. These findings suggest TES-4207 could make patients more responsive to ICI therapy, especially those with poor initial responses. Ongoing studies are further investigating its effects and potential in combination therapies."

IO biomarker • Melanoma • Oncology • Solid Tumor • CD8 • IFNG • IL2

First-in-class NR2F6 antagonist TES-ONC-07 enhances anti-cancer host immunity reducing tumor growth in a "cold" cancer model (AACR 2025) - "Potentially, treatment with TES-ONC-07 may increase sensitivity to ICI, also in those patients with limited response. Further studies are ongoing to test combination therapies as well as complete the preclinical development of TES-ONC-07."

IO biomarker • Preclinical • Melanoma • Oncology • Solid Tumor • CD4 • CD8 • IFNG • IL2

TES-4207, a first-in-class antagonist of the immune checkpoint NR2F6, drives anti-tumor immunity and enhances efficacy of PD-1 blockade (ESMO-IO 2025) - "These results suggest that targeting NR2F6 with TES-4207 could increase patient sensitivity to ICI therapy, particularly in those with limited response. Further preclinical development and combination studies are ongoing."

Clinical • IO biomarker • Melanoma • Oncology • Solid Tumor • CD8 • IFNG • IL2